Skip to main content
OpenTrials
Completed

NCT Number: NCT00521066

GYNECARE PROSIMA* Pelvic Floor Repair System for Pelvic Organ Prolapse

The purpose of this study is to is to evaluate the success of the GYNECARE PROSIMA* system in women with symptoms for pelvic organ prolapse (POP) requiring surgical correction of POP.

(*TRADEMARK)

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Royal Women's Hospital, Melbourne, Australia

Loading trial locations.

About this study

The GYNECARE PROSIMA* system provides a simplified mesh repair, avoiding the need for dissection outside the pelvic cavity.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Candidates with symptomatic pelvic organ prolapse of ICS POP-Q Stage II or III, suitable for surgical repair. Vaginal hysterectomy, perineal repair and/or mid urethral sling procedures for incontinence may be performed concurrently.
  • Age ≥ 18 years.
  • Agrees to participate in the study, including completion of all study-related procedures, evaluations and questionnaires, and documents this agreement by signing the Ethics Committee / IRB approved informed consent.

Exclusion criteria

  • Additional surgical intervention concurrent to the PROSIMA procedure (e.g. sacrocolpopexy, paravaginal repair, tubal sterilisation).
  • Previous repair of pelvic organ prolapse involving insertion of mesh.
  • Previous hysterectomy within 6 months of scheduled surgery.
  • Experimental drug or experimental medical device within 3 months prior to the planned procedure.
  • Active genital, urinary or systemic infection at the time of the surgical procedure. Surgery may be delayed in such subjects until the infection is cleared.
  • Coagulation disorder or on therapeutic anticoagulant therapy at the time of surgery.
  • History of chemotherapy or pelvic radiation therapy.
  • Systemic disease known to affect bladder or bowel function (e.g. Parkinson's disease, multiple sclerosis, spina bifida, spinal cord injury or trauma).
  • Current evaluation or treatment for chronic pelvic pain (e.g. interstitial cystitis, endometriosis, coccydynia, vulvodynia).
  • Nursing or pregnant or intends future pregnancy.
  • In the investigator's opinion, any medical condition or psychiatric illness that could potentially be life threatening or affect their ability to complete the study visits according to this protocol.

Treatment and study plan

GYNECARE PROSIMA* Pelvic Floor Repair System

Device

procedure for pelvic organ prolapse

Other names: mesh pelvic floor repari

Primary outcomes

  1. Success based on overall POP-Q score at 12 months post-procedure.

    Time frame: 12-months

    Success is determined by achievement of an overall POP-Q score of ICS Stage ≤1, without further re-intervention for POP.

Secondary outcomes

  1. Success based on overall POP-Q score at 24 months post-procedure.

    Time frame: 24 months

    Success is determined by achievement of an overall POP-Q score of ICS Stage ≤1, without further re-intervention for POP

  2. Success based on treated compartment ICS POP-Q stage

    Time frame: 12 months

    Success will be determined by achievement of treated compartment POP-Q score of ICS Stage ≤1, without further re-intervention for POP.

  3. Success based on treated compartment ICS POP-Q stage

    Time frame: 24 months

    Success will be determined by achievement of treated compartment POP-Q score of ICS Stage ≤1, without further re-intervention for POP.

  4. Success defined as the leading edge within the hymen

    Time frame: 12 months

    Success defined as the leading edge within the hymen (i.e. all POP-Q values to be less than 0, without further re-intervention for POP)

  5. Success defined as the leading edge within the hymen

    Time frame: 24 months

    Success defined as the leading edge within the hymen (i.e. all POP-Q values to be less than 0, without further re-intervention for POP)

  6. Mean PFDI-20 score

    Time frame: 12 months

  7. Mean PFDI-20 score

    Time frame: 24 months

  8. Mean change from baseline in PFDI-20 scores

    Time frame: 24 months

  9. Mean change from baseline in PFDI-20 scores

    Time frame: 12 months

  10. Mean POPDI score

    Time frame: 12 months

    POPDI is a sub score of PFDI-20

  11. Mean POPDI score

    Time frame: 24 months

    POPDI is a sub score of PFDI-20

  12. Mean change from baseline in POPDI score

    Time frame: 12 months

    POPDI is a sub scores of PFDI-20

  13. Mean change from baseline in POPDI score

    Time frame: 24 months

    POPDI is a sub score of PFDI-20

  14. Mean CRADI score

    Time frame: 12 months

    CRADI is a sub score of PFDI-20

  15. Mean CRADI score

    Time frame: 24 months

    CRADI is a sub score of PFDI-20

  16. Mean change from baseline in CRADI score

    Time frame: 12 months

    CRADI is a sub score of PFDI-20

  17. Mean change from baseline in CRADI score

    Time frame: 24 months

    CRADI is a sub score of PFDI-20

  18. Mean UDI score

    Time frame: 12 months

    UDI is a sub score of PFDI-20

  19. Mean UDI score

    Time frame: 24 months

    UDI is a sub score of PFDI-20

  20. Mean change from baseline in UDI score

    Time frame: 12 months

    UDI is a sub score of PFDI-20

  21. Mean change from baseline in UDI score

    Time frame: 24 months

    UDI is a sub score of PFDI-20

  22. EuroQol (EQ-5D health state) change from baseline

    Time frame: 12 months

  23. EuroQol (EQ-5D health state) change from baseline

    Time frame: 24 months

  24. Mean PFIQ-7 score

    Time frame: 12 months

  25. Mean PFIQ-7 score

    Time frame: 24 months

  26. Mean change from baseline in PFIQ-7 score

    Time frame: 12 months

  27. Mean change from baseline in PFIQ-7 score

    Time frame: 24 months

  28. Mean POPIQ score

    Time frame: 12 months

    POPIQ is a sub-score of PFIQ-7

  29. Mean POPIQ score

    Time frame: 24 months

    POPIQ is a sub-score of PFIQ-7

  30. Mean change from baseline in POPIQ score

    Time frame: 12 months

    POPIQ is a sub-score of PFIQ-7

  31. Mean change from baseline in POPIQ score

    Time frame: 24 months

    POPIQ is a sub-score of PFIQ-7

  32. Mean CRAIQ score

    Time frame: 12 months

    CRAIQ is a sub-score of PFIQ-7

  33. Mean CRAIQ score

    Time frame: 24 months

    CRAIQ is a sub-score of PFIQ-7

  34. Mean change from baseline in CRAIQ score

    Time frame: 12 months

    CRAIQ is a sub-score of PFIQ-7

  35. Mean change from baseline in CRAIQ score

    Time frame: 24 months

    CRAIQ is a sub-score of PFIQ-7

  36. Mean UIQ score

    Time frame: 12 months

    UIQ is a sub-score of PFIQ-7

  37. Mean UIQ score

    Time frame: 24 months

    UIQ is a sub-score of PFIQ-7

  38. Mean change from baseline in UIQ score

    Time frame: 12 months

    UIQ is a sub-score of PFIQ-7

  39. Mean change from baseline in UIQ score

    Time frame: 24 months

    UIQ is a sub-score of PFIQ-7

  40. Mean PISQ-12 score

    Time frame: 12 months

    In subjects sexually active at baseline, assessment of sexual function

  41. Mean PISQ-12 score

    Time frame: 24 months

    In subjects sexually active at baseline, assessment of sexual function

  42. Mean change from baseline in PISQ-12 score

    Time frame: 12 months

    In subjects sexually active at baseline, assessment of sexual function

  43. Mean change from baseline in PISQ-12 score

    Time frame: 24 months

    In subjects sexually active at baseline, assessment of sexual function

  44. Incidence of new onset dyspareunia, resolution or continuance of pre-existing dyspareunia

    Time frame: ongoing

  45. Length of procedure

    Time frame: perioperative

    From time to first incision to time of last suture used to secure VSD

  46. Pain score measured using Visual Analog Scale (VAS).

    Time frame: 24 hours post surgery and at the 3-4 week visit

  47. Discomfort of balloon removal, measured using VAS at time of removal.

    Time frame: 24 hrs post-surgical

  48. Subject perception of VSD: Awareness

    Time frame: 3-4 week visit

    Measured by visual analogue scale

  49. Subject perception of VSD: Discomfort

    Time frame: 3-4 week visit

    Measured by visual analogue scale

  50. Subject perception of VSD: Acceptability of discharge

    Time frame: 3-4 week visit

    Measured by visual analogue scale

  51. Subject global impression

    Time frame: 12 month visit

    assessed on a 5 point Likert scale

  52. Subject global impression

    Time frame: 24 month visit

    assessed on a 5 point Likert scale

Sponsors and collaborators

Lead sponsor

Ethicon, Inc.

Industry

Registry information

Official study title

A Prospective, Multi-centre Study to Evaluate the Clinical Performance of the GYNECARE PROSIMA* Pelvic Floor Repair System as a Procedure for Pelvic Organ Prolapse

Important dates

Study start
2007
Primary completion
2008
Study completion
2010
First posted
Aug 27, 2007
Registry last updated
May 6, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.